Clinical Trials

Urinary Bladder Neoplasms

NCT04633239 2026-03-18

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

42 enrolled

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05411094 2026-03-18

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

18 enrolled

Pancreatic Neoplasms

NCT05554328 2026-03-18

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04585958 2026-03-17

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

55 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03486873 2026-03-16

MK-3475-587

Other hematologic neoplasm

3,500 enrolled

Hematologic Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06353386 2026-03-13

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT07018622 2026-03-11

DAPA-ARMOR

46 enrolled

Other solid neoplasm

Solid Tumors

NCT07460180 2026-03-10

PROOV

55 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

57 enrolled

CNS

Glioma

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Breast Neoplasms

NCT07371104 2026-03-05

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

40 enrolled

Neoplasms, Ovarian Neoplasms

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

78 enrolled

CNS

Glioblastoma

NCT07024784 2026-03-04

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

377 enrolled

Phase EARLY_PHASE1 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

90 enrolled

Pancreatic Neoplasms

NCT06915025 2026-02-27

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02693535 2026-02-13

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

18 enrolled

BRCA1 Mutation

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

64 enrolled

Prostatic Neoplasms

NCT05498272 2026-01-23

NePtune

32 enrolled

Prostatic Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

554 enrolled

Endometrial Neoplasms

NCT02813135 2026-01-16

ESMART

472 enrolled

Tumor-Agnostic

Neoplasms

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

880 enrolled

Ovarian Neoplasms

NCT06856499 2026-01-09

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

50 enrolled

Fallopian Tube Neoplasms

NCT05524935 2026-01-08

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

37 enrolled

Dermatologic

Uveal Melanoma

NCT04711824 2025-12-23

SOLARA

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06545942 2025-12-23

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04550104 2025-12-19

CONCORDE

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04086485 2025-12-17

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

56 enrolled

EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT05568212 2025-12-01

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

176 enrolled

Thoracic

Non-small-cell Lung Cancer Patients

NCT05900895 2025-11-20

PHOEBE

6 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06785636 2025-11-14

P300

252 enrolled

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06130254 2025-10-14

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Other solid neoplasmThoracic

52 enrolled

Advanced Solid Tumor

NCT04644289 2025-10-03

WoO

Carcinoma, Ovarian Epithelial

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05093231 2025-09-18

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

20 enrolled

Pancreatic Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

429 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07151911 2025-09-03

ROYAL

Recruiting

100 enrolled

Breast Neoplasms

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

20 enrolled

Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

119 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02029001 2025-08-07

MOST plus

900 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06441747 2025-07-29

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

40 enrolled

Cholangiocarcinoma

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

24 enrolled

Ovarian Neoplasms

NCT05623319 2025-06-24

THOR